Aurinia Pharmaceuticals (AUPH) Stock Price Today—Real Time Charts and Quotes

Q: What are the 52-week high and low prices for Aurinia Pharmaceuticals (AUPH)?

AUPH has a 52-week high of $0 and a 52-week low of $0, with the current price at $0.

Q: What is the price-to-earnings (P/E) ratio of Aurinia Pharmaceuticals (AUPH)? What does it indicate?

The current P/E ratio (TTM) of AUPH is 7.462182192324566, indicating how much investors pay for each dollar of earnings. A higher P/E ratio often reflects stronger growth expectations, while a lower P/E ratio may suggest a more attractive valuation or slower growth. Comparing it with the average P/E of the Biotechnology industry for a better context.

Q: What is the market cap of Aurinia Pharmaceuticals (AUPH)?

Aurinia Pharmaceuticals (AUPH) currently has a market cap of approximately $2.13B.

Q: What is the most recent quarterly earnings per share (EPS) for Aurinia Pharmaceuticals (AUPH)?

Aurinia Pharmaceuticals (AUPH)'s diluted earnings per share (Diluted EPS) is 2.137444461809819. EPS = Net Income / Total Diluted Shares, which is a key metric for measuring a company's profitability.

Q: Should you buy or sell Aurinia Pharmaceuticals (AUPH) now?

As of now, AUPH is trading at $0, with a P/E ratio of 7.462182192324566 and a diluted EPS of 2.137444461809819. Your buy or sell decisions should be based on your investment goals and risk tolerance. We recommend making an overall judgment by considering Aurinia Pharmaceuticals's financial reports, the outlook of the Biotechnology sector, and your own holdings. Investing involves risk—please make decisions prudently.

Q: What factors can affect the stock price of Aurinia Pharmaceuticals (AUPH)?

Key factors include: company quarterly reports (revenue, EPS), competition and trends in the Biotechnology sector, macroeconomic environment (interest rate, inflation), market sentiment, as well as major events like product releases and mergers & acquisitions.

Q: How to buy Aurinia Pharmaceuticals (AUPH) stock?

You can buy Aurinia Pharmaceuticals (AUPH) through Gate. Sign up for a Gate account and complete identity verification, then go to the Aurinia Pharmaceuticals trading page to make a purchase. Gate supports fractional share trading, so you can start investing without buying a whole share.

$0

+$0(0,00%)

Geen gegevens

*Data last updated: 2026-04-29 06:44 (UTC+8)

As of 2026-04-29 06:44, Aurinia Pharmaceuticals (AUPH) is priced at $0, with a total market cap of $2,13B, a P/E ratio of 7,46, and a dividend yield of 0,00%. Today, the stock price fluctuated between $0 and $0. The current price is 0,00% above the day's low and 0,00% below the day's high, with a trading volume of 823,22K. Over the past 52 weeks, AUPH has traded between $0 to $0, and the current price is 0,00% away from the 52-week high.

AUPH Key Stats

Yesterday's Close$16

Market Cap$2,13B

Volume823,22K

P/E Ratio7,46

Dividend Yield (TTM)0,00%

Diluted EPS (TTM)2,13

Net Income (FY)$287,20M

Revenue (FY)$283,05M

Earnings Date2026-05-11

EPS Estimate0,18

Revenue Estimate$76,97M

Shares Outstanding130,29M

Beta (1Y)1.523

About AUPH

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

SectorHealthcare

IndustryBiotechnology

CEOKevin C. Tang

HeadquartersEdmonton,BC,CA

Official Websitehttps://www.auriniapharma.com

Employees (FY)128,00

Average Revenue (1Y)$2,21M

Net Income per Employee$2,24M

Aurinia Pharmaceuticals (AUPH) FAQ

What's the stock price of Aurinia Pharmaceuticals (AUPH) today?

x

Aurinia Pharmaceuticals (AUPH) is currently trading at $0, with a 24h change of 0,00%. The 52-week trading range is $0–$0.

What are the 52-week high and low prices for Aurinia Pharmaceuticals (AUPH)?

x

What is the price-to-earnings (P/E) ratio of Aurinia Pharmaceuticals (AUPH)? What does it indicate?

x

What is the market cap of Aurinia Pharmaceuticals (AUPH)?

x

What is the most recent quarterly earnings per share (EPS) for Aurinia Pharmaceuticals (AUPH)?

x

Should you buy or sell Aurinia Pharmaceuticals (AUPH) now?

x

What factors can affect the stock price of Aurinia Pharmaceuticals (AUPH)?

x

How to buy Aurinia Pharmaceuticals (AUPH) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Aurinia Pharmaceuticals Prijs